Gail Kuslansky1, Herman Buschke, Mindy Katz, Martin Sliwinski, Richard B Lipton. 1. Department of Neurology, Rose F. Kennedy Center for Mental Retardation and Developmental Disabilities, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA. kuslansk@aecom.yu.edu
Abstract
OBJECTIVES: To improve screening for Alzheimer's disease (AD) with the Memory Impairment Screen (MIS), a 4-minute, four-item delayed free and cued recall memory test with controlled learning and high discriminative validity. To assess the discriminative validity of the MIS for AD and to compare it with the conventional three-word memory test, a delayed free recall task, widely recommended as a dementia-screening test in clinical practice. DESIGN: Cross-sectional validation study nested within a longitudinal study of aging and dementia. The MIS and the standard three-word memory task were administered as part of a comprehensive neurological and neuropsychological evaluation. SETTING: Einstein Aging Study at the Albert Einstein College of Medicine, Bronx, New York. PARTICIPANTS: Two hundred forty community-dwelling older adults. MEASUREMENTS: Sensitivity, specificity, and positive predictive value (PPV) were calculated for the MIS and three-word memory test as screening tests for AD. RESULTS: In comparison with the three-word memory task, the MIS had higher sensitivity (.86 vs.65), higher specificity (.97 vs.85), and greater PPV (.80 vs.37) as a screen for AD. CONCLUSIONS: The MIS had high discriminative validity as a screening test for AD and substantially outperformed the three-word memory task. Given its validity and brevity, the MIS has important advantages as an AD screen for use in primary care.
OBJECTIVES: To improve screening for Alzheimer's disease (AD) with the Memory Impairment Screen (MIS), a 4-minute, four-item delayed free and cued recall memory test with controlled learning and high discriminative validity. To assess the discriminative validity of the MIS for AD and to compare it with the conventional three-word memory test, a delayed free recall task, widely recommended as a dementia-screening test in clinical practice. DESIGN: Cross-sectional validation study nested within a longitudinal study of aging and dementia. The MIS and the standard three-word memory task were administered as part of a comprehensive neurological and neuropsychological evaluation. SETTING: Einstein Aging Study at the Albert Einstein College of Medicine, Bronx, New York. PARTICIPANTS: Two hundred forty community-dwelling older adults. MEASUREMENTS: Sensitivity, specificity, and positive predictive value (PPV) were calculated for the MIS and three-word memory test as screening tests for AD. RESULTS: In comparison with the three-word memory task, the MIS had higher sensitivity (.86 vs.65), higher specificity (.97 vs.85), and greater PPV (.80 vs.37) as a screen for AD. CONCLUSIONS: The MIS had high discriminative validity as a screening test for AD and substantially outperformed the three-word memory task. Given its validity and brevity, the MIS has important advantages as an AD screen for use in primary care.
Authors: Diana Matallana; Cecilia de Santacruz; Carlos Cano; Pablo Reyes; Rafael Samper-Ternent; Kyriakos S Markides; Kenneth J Ottenbacher; Carlos A Reyes-Ortiz Journal: J Geriatr Psychiatry Neurol Date: 2010-06-10 Impact factor: 2.680
Authors: Christopher R Carpenter; Elizabeth R Bassett; Grant M Fischer; Jonathan Shirshekan; James E Galvin; John C Morris Journal: Acad Emerg Med Date: 2011-04 Impact factor: 3.451
Authors: Breda Cullen; Brian O'Neill; Jonathan J Evans; Robert F Coen; Brian A Lawlor Journal: J Neurol Neurosurg Psychiatry Date: 2006-12-18 Impact factor: 10.154
Authors: Valeria L Torres; Clara Vila-Castelar; Yamile Bocanegra; Ana Baena; Edmarie Guzmán-Vélez; Daniel C Aguirre-Acevedo; Victoria Tirado; Claudia Munoz; Eliana Henao; Sonia Moreno; Margarita Giraldo; Natalia Acosta; Silvia Rios Romenets; Jessica B Langbaum; William Cho; Eric M Reiman; Pierre N Tariot; Monica Rosselli; Yakeel T Quiroz; Francisco Lopera Journal: Appl Neuropsychol Adult Date: 2019-06-23 Impact factor: 2.248